Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Doribax er større end risiciene ved behandling af nosokomiel pneumoni, komplicerede infektioner i maven og komplicerede urinvejsinfektioner hos voksne.
The Committee for Medicinal Products for Human Use (CHMP) decided that Doribax’ s benefits are greater than its risks for the treatment of nosocomial pneumonia, complicated intra-abdominal infections and complicated urinary tract infections in adults.